



Pluristem and United Therapeutics Announce Closing of the Exclusive License Agreement to Develop and Commercialize PLX Cells for the Treatment of Pulmonary Hypertension

HAIFA, ISRAEL, August 3, 2011 -- [Pluristem Therapeutics Inc.](#) (NasdaqCM: PSTI; TASE: PLTR) today announced that following the consent of the Office of the Chief Scientist of Israel, Pluristem's exclusive out-license agreement signed on June 19, 2011 with United Therapeutics Corporation (NasdaqGS: UTHR) for the use of Pluristem's PLacental eXpanded (PLX) cells to develop and commercialize a cell-based product for the treatment of Pulmonary Hypertension (PH) has become effective as of August 2, 2011.

About United Therapeutics Corporation

United Therapeutics Corporation (NasdaqGS: UTHR) is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions, including cardiovascular, cancer, and infectious diseases.

About Pluristem Therapeutics

Develop and Commercialize PLX Cells for the Treatment of Pulmonary Hypertension

Écrit par Pluristem

Lundi, 22 Août 2011 13:00 -

Pluristem Therapeutics Inc. (NasdaqCM: PSTI; TASE: PLTR) is a leading developer of standardized cell therapy products for the treatment of life threatening diseases. The company's patented PLX (PLacental eXpanded) cells drug delivery platform releases a cocktail of therapeutic proteins in response to a host of local and systemic inflammatory diseases. PLX cells are grown using the company's proprietary 3D micro-environmental technology and are an off-the-shelf product that requires no tissue matching prior to administration. Data from two phase I studies indicate that Pluristem's first PLX product candidate, PLX-PAD, is safe and potentially effective for the treatment of end stage peripheral artery disease. Pluristem's pre-clinical animal models have demonstrated PLX cells are also potentially effective in nerve pain and muscle damage, when administered locally, and in inflammatory bowel disease, MS and stroke, when administered systemically.

Pluristem has a strong patent portfolio, GMP certified manufacturing and research facilities, strategic relationships with major research institutions and a seasoned management team.

For more information visit www.pluristem.com, or follow us on Twitter [@Pluristem](https://twitter.com/Pluristem), the contents of which are not part of this press release.